본문바로가기
About Us
SK bioscience
Company Overview
History
Vision
Contact Us
Leadership
Message from the CEO
Headquarters & Facilities
SK bioscience Headquarters
R&D Center
L HOUSE
Subsidiary
SK bioscience USA
IDT Biologika
Science & Technology
Pipeline
R&D
Production
Business
Business Overview
Domestic
Overseas Business
Vaccine Co-Development
and Technology Transfer
CDMO/CMO
Products
In-house Products
Outsourced Products
Global Partnerships
ESG
새창열기 아이콘
IR
Corporate Governance
Company Information
Financial Information
Financial Statements
Financial Credit
Audit Reports
Investment Information
Stock Prices
Shareholder Status
IR Documents
Disclosure
PR
Press Releases
Media Zoom
Brochure
CI Guideline
sitemap
About Us
SK bioscience
Company Overview
History
Vision
Contact Us
Leadership
Message from the CEO
Headquarters & Facilities
SK bioscience Headquarters
R&D Center
L HOUSE
Subsidiary
SK bioscience USA
IDT Biologika
Science & Technology
Pipeline
R&D
Production
Business
Business Overview
Domestic
Overseas Business
Vaccine Co-Development
and Technology Transfer
CDMO/CMO
Products
In-house Products
Outsourced Products
Global Partnerships
ESG
IR
Corporate Governance
Company Information
Financial Information
Financial Statements
Financial Credit
Audit Reports
Investment Information
Stock Prices
Shareholder Status
IR Documents
Disclosure
PR
Press Releases
Media Zoom
Brochure
CI Guideline
사이트맵 닫기
Language
KOR
ENG
LinkedIn
YouTube
ESG
SK careers
C/S
SK ethics
Q
U
I
C
K
PR
SK bioscience company news updates
PR
About Us
Science & Technology
Business
ESG
IR
PR
Press Releases
Press Releases
Media Zoom
Brochure
CI Guideline
Press Releases
SK bioscience Receives Approval for Clinical Trials of 21-valent Pneumococcal Vaccine Candidate in China
2025.07.18
SK bioscience Submits IND for Phase 1/2 Clinical Trial of Adjuvanted Influenza Vaccine Candidate
2025.07.17
SK bioscience Celebrates Completion of New Vaccine Production Facility for Global Market, Advancing Partnership with Sanofi
2025.06.30
SK bioscience Strengthens ESG Commitment through Invasive Plant Removal Activities
2025.06.17
SK bioscience Expands Manufacturing Facility to Boost Global Vaccine Supply
2025.05.29
SK bioscience Wins Patent Lawsuit Against Pfizer Over Pneumococcal Vaccine
2025.05.21
IDT Biologika Ramps Up Global Outreach to Expand Strategic CDMO Partnership
2025.05.20
SK bioscience and Korea Disease Control and Prevention Agency Initiate Development of Avian Influenza Vaccine
2025.05.06
SK bioscience and IVI Host 2025 Park MahnHoon Award
2025.05.01
SK bioscience Wins Patent Invalidation Case Against Moderna, Accelerating mRNA Vaccine Development
2025.04.23
SK bioscience and IVI Announce the 2025 Recipients of the ‘Park MahnHoon Award’ Four Honorees Recognized for Contributions to Polio Vaccine Development and Global Immunization Efforts
2025.03.25
SK bioscience Expands Influenza Vaccine Exports to Southern Hemisphere Market
2025.03.12
처음
이전
1
2
3
4
5
6
7
8
9
10
다음
끝
